Idera Announces Agreement with Abbott to Develop a Companion Diagnostic for IMO-8400 in Genetically Defined Forms of B-cell Lymphoma
- IMO-8400 is in clinical development for the potential treatment of two genetically defined forms of B-cell lymphoma characterized by the presence of the oncogenic mutation MYD88 L265P –
Under the agreement, Abbott will develop a test utilizing polymerase
chain reaction (PCR) technology to identify the presence of the MYD88
L265P oncogenic mutation in tumor biopsy samples with high sensitivity
and specificity. This mutation, which can be identified in approximately
90% of patients with Waldenström’s macroglobulinemia and approximately
30% of patients with the
“Research by Idera and by independent investigators has established TLR
antagonism as a potentially promising and novel therapeutic approach for
patients with B-cell malignancies harboring the MYD88 L265P mutation,”
said
About IMO-8400
Idera’s Toll-like receptor (TLR) antagonist drug candidates have been
created using a proprietary chemistry-based drug discovery platform.
IMO-8400 is a first-in-class synthetic oligonucleotide-based antagonist
of TLRs 7, 8, and 9. In
About
Forward Looking Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. All
statements, other than statements of historical fact, included or
incorporated in this press release, including statements regarding the
Company’s strategy, future operations, collaborations, intellectual
property, cash resources, financial position, future revenues, projected
costs, prospects, plans, and objectives of management, are
forward-looking statements. The words “believes,” “anticipates,”
“estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,”
“potential,” “likely,” “projects,” “continue,” “will,” and “would” and
similar expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying
words. Idera cannot guarantee that it will actually achieve the plans,
intentions or expectations disclosed in its forward-looking statements
and you should not place undue reliance on the Company’s forward-looking
statements. There are a number of important factors that could cause
Idera’s actual results to differ materially from those indicated or
implied by its forward-looking statements. Factors that may cause such a
difference include: whether results obtained in preclinical studies and
clinical trials such as the results described in this release will be
indicative of the results that will be generated in future clinical
trials, including in clinical trials in different disease indications;
whether products based on Idera’s technology will advance into or
through the clinical trial process on a timely basis or at all and
receive approval from the
Source:
Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
larcudi@iderapharma.com
or
Stern
Investor Relations, Inc.
Sarah McCabe, 212-362-1200
sarah@sternir.com